Lipoxygenase catalyzed metabolites derived from docosahexaenoic acid are promising antitumor agents against breast cancer

Docosahexaenoic acid (DHA) is known to inhibit breast cancer in the rat. Here we investigated whether DHA itself or select metabolites can account for its antitumor action. We focused on metabolites derived from the lipoxygenase (LOX) pathway since we previously showed that they were superior anti-proliferating agents compared to DHA; 4-OXO-DHA was the most potent. A lipidomics approach detected several LOX-metabolites in plasma and the mammary gland in rats fed DHA; we also identified for the first time, 4-OXO-DHA in rat plasma. In a reporter assay, 4-OXO-DHA and 4-HDHA were more effective activators of PPAR? than DHA. In breast cancer cell lines, 4-OXO-DHA induced PPAR gamma and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) but inhibited the activity of NF-kappa B and suppressed PI3K and mTOR signaling. Because of the structural characteristics of 4-OXO-DHA (Michael acceptor), not shared by any of the other hydroxylated-DHA, we used MS and showed that it can covalently modify the cysteine residue of NF-kappa B. We have also shown that the chemopreventive effect of DHA is associated with significant reduction of PGE(2) levels, in both rat mammary tumors induced by MNU and non-involved mammary tissues. Collectively, our results indicate that 4-OXO-DHA is the metabolite of choice in future chemoprevention studies.

Automated summary

The study found that 4-OXO-DHA is the preferred metabolite in future chemoprevention studies, with the ability to combat breast cancer through pathways such as activating PPAR-ɣ and 15-PGDH.